Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.64 |
| ▸ | USP1 | O94782 | 11/20 | 0.54 |
| ▸ | WDR48 | Q8TAF3 | 10/20 | 0.54 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423567 | 0.84 | USP1 (0.66) | TRPM8USP1WDR48PIP4K2CMITF | |
| SCHEMBL30462061 | 0.81 | USP1 (0.43) | TRPM8USP1WDR48PIP4K2CMAPT | |
| SCHEMBL29043874 | 0.81 | USP1 (0.43) | TRPM8USP1WDR48PIP4K2CMAPT | |
| SCHEMBL29043921 | 0.81 | TRPM8 (0.65) | TRPM8MITFLMNAMAPTSMN1; SMN2 | |
| SCHEMBL30462040 | 0.81 | TRPM8 (0.65) | TRPM8MITFLMNAMAPTSMN1; SMN2 | |
| SCHEMBL31423569 | 0.79 | USP1 (0.51) | TRPM8USP1WDR48 | |
| SCHEMBL1442185 | 0.79 | TRPM8 (1.00) | TRPM8MITFLMNAMAPTSMN1; SMN2 | |
| SCHEMBL31423632 | 0.75 | USP1 (0.75) | USP1WDR48PIP4K2C | |
| SCHEMBL1442021 | 0.74 | TRPM8 (0.89) | TRPM8MITFLMNAMAPTSMN1; SMN2 | |
| SCHEMBL31423693 | 0.74 | USP1 (0.55) | TRPM8USP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | TRPM8 4791/4885USP1 1/4885WDR48 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.